Idexx Laboratories (IDXX) AI Stock Analysis

Company Guidance

For full year 2026, IDEXX raised its revenue outlook to $4.741 billion to $4.767 billion, a $32 million increase at midpoint, with reported revenue growth of 10.1% to 10.8%, overall organic revenue growth of 9.3% to 10%, and organic CAG Diagnostics recurring revenue growth of 10.3% to 11%, including approximately 4% benefit from global net price realization; the ranges represent an increase of approximately 60 basis points at midpoint along with tightening the low end of the range. EPS guidance increased to $14.96 to $15.16 per share, a $0.25 per share increase at midpoint, reflecting 15% to 16% comparable EPS growth, a tax rate estimated at 20.5%, lower net interest expense of approximately $32 million, approximately $0.13 per share of dilution related to ezyVet, $0.25 per share of foreign exchange benefits, $19 million or $0.24 per share of share-based compensation benefits, and a 2% reduction in average diluted shares outstanding. Reported operating margin guidance is 32.1% to 32.3%, reflecting 50 to 70 basis points of full year comparable operating margin improvement and approximately 30 basis points of negative impact related to ezyVet; free cash flow conversion is expected to be 95% to 100% of net income, with capital spending of approximately $160 million. For the fourth quarter, reported operating margins are expected to be 28.4% to 29.3%, with an approximately 70-basis-point headwind from foreign currency partially offset by benefits from the ezyVet acquisition; a 1% strengthening of the US dollar would reduce revenue by approximately $4 million and EPS by $0.02 per share for the remainder of the year.